Cerdulatinib HCl (PRT-2070; PRT-062070)

Description: Cerdulatinib HCl (formerly PRT2070; PRT062070) is a novel, potent, selective orally bioactive, and multi-targeted tyrosine kinase inhibitor of JAK1/2/3/TYK2 and Syk with potential antitumor activity. It inhibits JAK1/JAK2/JAK3/TYK2 and Syk with IC50s of 12 nM/6 nM/8 nM/0.5 nM and 32 nM, respectively. It shows potent in vitro antiproliferative activity and high in vivo antitumor efficacy. Cerdulatinib also inhibits 19 other tested kinases with IC50 less than 200 nM. It is currently being studied in patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations.

References: J Pharmacol Exp Ther. 2014 Dec; 351(3):538-48.

Related CAS: 1198300-79-6 (free base); 1369761-01-2 (HCl);

PRT062070; PRT 062070; PRT062070, PRT2070; PRT2070; PRT-2070; PRT 2070; PRT-06270

0Chemical Name: 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide hydrochloride

InChi Key: BGLPECHZZQDNCD-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H27N7O3S/c1-2-31(29, 30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8, 13-14H, 2-4, 9-12H2, 1H3, (H2, 21, 28)(H2, 22, 23, 24, 25)

SMILES Code: O=C(C1=CN=C(NC2=CC=C(N3CCN(S(=O)(CC)=O)CC3)C=C2)N=C1NC4CC4)N